AbbVie (NYSE:ABBV) Stock Price Down 1% – What’s Next?

Shares of AbbVie Inc. (NYSE:ABBV) dropped 1% on Tuesday. The stock traded as low as $284.70 and last traded at $285.88. 5,336,668 shares traded hands during mid-day trading, a decline of 16% from the average daily volume of 6,328,662 shares. The stock had previously closed at $288.84.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Strong results and outlook: AbbVie reported $17.4 billion in third-quarter revenue and raised its full-year adjusted earnings guidance, reinforcing its growth case. The results helped lift shares recently. Article: AbbVie Stock Climbs as Q3 Earnings Fuel Growth Case
• Positive Sentiment: Pipeline expansion: AbbVie licensed global rights to Nxera Pharma’s experimental oral IBD drug NXE0033744, agreeing to pay $100 million upfront and up to $1.37 billion in development and commercial milestones, plus royalties. The deal adds a potential new treatment to its pipeline, though it remains investigational. Article: AbbVie Pens $1.4B Deal for Deprioritized IBD Drug from Nxera
• Positive Sentiment: Constructive investor sentiment: Recent coverage highlights analyst optimism and AbbVie’s defensive appeal as technology stocks retreat; the company has also recently reached a new 52-week high. These factors may support demand, but can also leave the stock vulnerable to a pullback after a strong advance. Article: Are Wall Street Analysts Bullish on AbbVie Stock?
• Neutral Sentiment: Additional R&D investment: AbbVie plans to invest £120 million to expand its Oxford research facility, supporting longer-term drug development but requiring time to translate into commercial returns. Article: AbbVie Invests £120m in UK Expansion
• Negative Sentiment: Oncology setback: AbbVie discontinued a Phase 2 solid-tumor drug program after seeing limited benefit, a reminder that clinical development carries risk and may weigh on expectations for its pipeline. Article: AbbVie Abandons Phase 2 Solid Tumor Drug Over Limited Benefit

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on ABBV shares. Leerink Partners lifted their target price on shares of AbbVie from $309.00 to $342.00 and gave the company an “outperform” rating in a research report on Monday. Guggenheim increased their price target on shares of AbbVie from $288.00 to $322.00 and gave the stock a “buy” rating in a report on Monday. Canaccord Genuity Group increased their price target on shares of AbbVie from $290.00 to $338.00 and gave the stock a “buy” rating in a report on Monday. Oppenheimer raised their price objective on shares of AbbVie from $244.00 to $258.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. Finally, Bank of America reaffirmed a “buy” rating on shares of AbbVie in a report on Tuesday, September 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and an average target price of $297.46.

AbbVie Stock Performance

The stock has a market capitalization of $509.91 billion, a P/E ratio of 22.98, a price-to-earnings-growth ratio of 1.34 and a beta of 0.20. The firm has a 50-day moving average price of $271.31 and a 200 day moving average price of $238.65.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, beating analysts’ consensus estimates of $3.73 by $0.09. The company had revenue of $17.40 billion for the quarter, compared to analysts’ expectations of $17.32 billion. AbbVie had a negative return on equity of 450.55% and a net margin of 15.67%. AbbVie’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the firm posted $1.86 EPS. On average, equities analysts anticipate that AbbVie Inc. will post 13.99 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Shareholders of record on Friday, January 15th will be paid a $1.82 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.73. This represents a $7.28 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Friday, January 15th. AbbVie’s payout ratio is presently 119.10%.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.06% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Burk Holdings LLC purchased a new stake in AbbVie during the 2nd quarter valued at about $30,000. Marquette Asset Management LLC raised its stake in shares of AbbVie by 52.2% in the second quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock worth $35,000 after purchasing an additional 48 shares during the last quarter. IMG Wealth Management Inc. raised its stake in shares of AbbVie by 3,060.0% in the second quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock worth $40,000 after purchasing an additional 153 shares during the last quarter. Principia Wealth Advisory LLC lifted its holdings in shares of AbbVie by 38.9% during the second quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock worth $40,000 after purchasing an additional 44 shares during the period. Finally, Tacita Capital Inc acquired a new stake in shares of AbbVie during the second quarter worth about $42,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.